Extravascular Dermal Trypanosomes in Suspected and Confirmed Cases of gambiense Human African Trypanosomiasis.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 10 04 2020
accepted: 25 06 2020
pubmed: 9 7 2020
medline: 8 7 2021
entrez: 9 7 2020
Statut: ppublish

Résumé

The diagnosis of gambiense human African trypanosomiasis (gHAT) typically involves 2 steps: a serological screen, followed by the detection of living trypanosome parasites in the blood or lymph node aspirate. Live parasites can, however, remain undetected in some seropositive individuals, who, we hypothesize, are infected with Trypanosoma brucei gambiense parasites in their extravascular dermis. To test this hypothesis, we conducted a prospective observational cohort study in the gHAT focus of Forecariah, Republic of Guinea. Of the 5417 subjects serologically screened for gHAT, 66 were enrolled into our study and underwent a dermatological examination. At enrollment, 11 seronegative, 8 unconfirmed seropositive, and 18 confirmed seropositive individuals had blood samples and skin biopsies taken and examined for trypanosomes by molecular and immunohistological methods. In seropositive individuals, dermatological symptoms were significantly more frequent, relative to seronegative controls. T.b. gambiense parasites were present in the blood of all confirmed cases (n = 18) but not in unconfirmed seropositive individuals (n = 8). However, T. brucei parasites were detected in the extravascular dermis of all unconfirmed seropositive individuals and all confirmed cases. Skin biopsies of all treated cases and most seropositive untreated individuals progressively became negative for trypanosomes 6 and 20 months later. Our results highlight the skin as a potential reservoir for African trypanosomes, with implications for our understanding of this disease's epidemiology in the context of its planned elimination and underlining the skin as a novel target for gHAT diagnostics.

Sections du résumé

BACKGROUND
The diagnosis of gambiense human African trypanosomiasis (gHAT) typically involves 2 steps: a serological screen, followed by the detection of living trypanosome parasites in the blood or lymph node aspirate. Live parasites can, however, remain undetected in some seropositive individuals, who, we hypothesize, are infected with Trypanosoma brucei gambiense parasites in their extravascular dermis.
METHODS
To test this hypothesis, we conducted a prospective observational cohort study in the gHAT focus of Forecariah, Republic of Guinea. Of the 5417 subjects serologically screened for gHAT, 66 were enrolled into our study and underwent a dermatological examination. At enrollment, 11 seronegative, 8 unconfirmed seropositive, and 18 confirmed seropositive individuals had blood samples and skin biopsies taken and examined for trypanosomes by molecular and immunohistological methods.
RESULTS
In seropositive individuals, dermatological symptoms were significantly more frequent, relative to seronegative controls. T.b. gambiense parasites were present in the blood of all confirmed cases (n = 18) but not in unconfirmed seropositive individuals (n = 8). However, T. brucei parasites were detected in the extravascular dermis of all unconfirmed seropositive individuals and all confirmed cases. Skin biopsies of all treated cases and most seropositive untreated individuals progressively became negative for trypanosomes 6 and 20 months later.
CONCLUSIONS
Our results highlight the skin as a potential reservoir for African trypanosomes, with implications for our understanding of this disease's epidemiology in the context of its planned elimination and underlining the skin as a novel target for gHAT diagnostics.

Identifiants

pubmed: 32638003
pii: 5868540
doi: 10.1093/cid/ciaa897
pmc: PMC8246823
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-20

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209511/Z/17/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Trop Med Int Health. 2004 May;9(5):542-50
pubmed: 15117297
PLoS Biol. 2019 Jan 11;17(1):e3000105
pubmed: 30633739
Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):905-13
pubmed: 21901632
Microbes Infect. 2011 Oct;13(11):943-52
pubmed: 21658462
Lancet. 2017 Nov 25;390(10110):2397-2409
pubmed: 28673422
Parasite. 2011 Nov;18(4):295-302
pubmed: 22091459
Elife. 2016 Sep 22;5:
pubmed: 27653219
Trans R Soc Trop Med Hyg. 1970;64(6):797-817
pubmed: 5495630
Biochem J. 1998 Nov 1;335 ( Pt 3):681-9
pubmed: 9794811
PLoS Negl Trop Dis. 2018 Dec 6;12(12):e0006890
pubmed: 30521525
Expert Rev Mol Diagn. 2015 May;15(5):607-15
pubmed: 25786994
Lancet Infect Dis. 2020 Feb;20(2):e38-e46
pubmed: 31879061
Am J Trop Med Hyg. 2002 Sep;67(3):289-95
pubmed: 12408669
PLoS Pathog. 2016 Jul 21;12(7):e1005744
pubmed: 27441553
Trends Parasitol. 2016 Feb;32(2):157-168
pubmed: 26643519
Trends Parasitol. 2018 Mar;34(3):197-207
pubmed: 29396200
PLoS Negl Trop Dis. 2016 Feb 18;10(2):e0004441
pubmed: 26890882
Arch Dermatol. 1995 Oct;131(10):1178-82
pubmed: 7574836
Infect Immun. 1993 Nov;61(11):4540-5
pubmed: 8406850
Acta Trop. 1995 Dec;60(3):189-99
pubmed: 8907397

Auteurs

Mariame Camara (M)

Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea.

Alseny M'mah Soumah (AM)

Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea.
Service de Dermatologie, Hôpital de Donka,Conakry, Guinea.

Hamidou Ilboudo (H)

Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea.
Institut de Recherche en Sciences de la Santé (IRSS)-Unité de Recherche Clinique de Nanoro (URCN), Nanoro, Burkina-Faso.
Institut de Recherche pour le Développement, Unité Mixte de Recherche Institut de Recherche pour le Développement (IRD)-CIRAD 177 InterTryp, Campus International de Baillarguet, Montpellier, France.

Christelle Travaillé (C)

Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut National de la Santé et de la Recherche Médicale (INSERM) U1201 and Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.

Caroline Clucas (C)

Wellcome Centre for Integrative Parasitology, College of Medical, Veterinary, and Life Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland, United Kingdom.

Anneli Cooper (A)

Wellcome Centre for Integrative Parasitology, College of Medical, Veterinary, and Life Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland, United Kingdom.

Nono-Raymond Kuispond Swar (NR)

Wellcome Centre for Integrative Parasitology, College of Medical, Veterinary, and Life Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland, United Kingdom.
Department of Parasitology, National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.

Oumou Camara (O)

Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea.

Ibrahim Sadissou (I)

Institut de Recherche pour le Développement, Unité Mixte de Recherche Institut de Recherche pour le Développement (IRD)-CIRAD 177 InterTryp, Campus International de Baillarguet, Montpellier, France.

Estefania Calvo Alvarez (E)

Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut National de la Santé et de la Recherche Médicale (INSERM) U1201 and Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.

Aline Crouzols (A)

Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut National de la Santé et de la Recherche Médicale (INSERM) U1201 and Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.

Jean-Mathieu Bart (JM)

Institut de Recherche pour le Développement, Unité Mixte de Recherche Institut de Recherche pour le Développement (IRD)-CIRAD 177 InterTryp, Campus International de Baillarguet, Montpellier, France.

Vincent Jamonneau (V)

Institut de Recherche pour le Développement, Unité Mixte de Recherche Institut de Recherche pour le Développement (IRD)-CIRAD 177 InterTryp, Campus International de Baillarguet, Montpellier, France.

Mamadou Camara (M)

Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea.

Annette MacLeod (A)

Wellcome Centre for Integrative Parasitology, College of Medical, Veterinary, and Life Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland, United Kingdom.

Bruno Bucheton (B)

Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea.
Institut de Recherche pour le Développement, Unité Mixte de Recherche Institut de Recherche pour le Développement (IRD)-CIRAD 177 InterTryp, Campus International de Baillarguet, Montpellier, France.

Brice Rotureau (B)

Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut National de la Santé et de la Recherche Médicale (INSERM) U1201 and Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH